PDS Biotechnology Corporation (PDSB) Stock Forecast
PDSB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $5.00 average of analyst targets
- Upside to target
- +342.5% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.11
- 52-week range
- $0.20 – $1.60
PDSB analyst ratings
2 analystsNumber of analysts at each rating.
PDSB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PDSB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.11 | −$0.11 | −$0.19 | +42.1% | 1 |
| Current fiscal year (2026) | −$0.49 | −$0.49 | −$0.49 | −$0.74 | +33.8% | 1 |
| Next fiscal year (2027) | −$0.34 | −$0.39 | −$0.30 | −$0.49 | +29.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PDSB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
PDSB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PDSB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.12 | −$0.11 | −$0.11 | −$0.11 | −5.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.50 | −$0.50 | −$0.49 | −$0.49 | −$0.49 | −1.3% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.47 | −$0.41 | −$0.36 | −$0.34 | −$0.34 | −26.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PDSB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PDSB beat in 10 of 12.
What analysts expect from PDSB
2 analysts cover PDS Biotechnology; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.00, 342.5% above the latest close of $1.13. Analysts expect earnings of −$0.49 per share for 2026, +33.8% from a year earlier. For 2027 the average estimate is −$0.34 per share. PDS Biotechnology beat the EPS estimate in 10 of the last 12 quarters.
Related: PDSB income statement, PDSB key metrics, PDSB chart. See the PDSB stock overview for the latest quote and news.
PDSB forecast FAQ
What is PDS Biotechnology's price target?
The average analyst price target for PDS Biotechnology is $5.00, 342.5% above the latest close of $1.13.
Is PDS Biotechnology a buy, hold or sell?
Of 2 analysts covering PDS Biotechnology, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is PDS Biotechnology's EPS forecast?
Analysts forecast −$0.49 per share for 2026 (range −$0.49 to −$0.49); for 2027 the estimate is −$0.34.
When does PDS Biotechnology report earnings?
PDS Biotechnology is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.11.
Does PDS Biotechnology usually beat earnings estimates?
PDS Biotechnology reported EPS at or above the analyst estimate in 10 of the last 12 quarters.